Gene that drives blood cancer drug resistance uncovered with new CRISPR activation tool
Scientists have identified a gene called Irx5 that contributes to drug resistance in blood cancer patients using a new CRISPR activation tool called Partita. This discovery helps explain why some cancer cells survive targeted therapies like venetoclax.
Why it matters
Understanding the genetic mechanisms of treatment resistance is critical for developing more effective cancer therapies and overcoming patient relapse.
by Olivia Newton-John Cancer Research Institute
edited by Gaby Clark , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Unsplash/CC0 Public Domain Researchers have uncovered a previously unknown gene that causes resistance to a leading blood cancer drug, as well as several genes that accelerate lymphoma growth, using a powerful new CRISPR activation library.
Traditional CRISPR is a genetic engineering tool that allows scientists to easily delete specific genes in an organism's DNA and assess their role and importance. It has become a cornerstone technology in cancer research.
A newer frontier is CRISPR activation , a technique that enables the activation of specific genes. It offers valuable insights into the roles of certain genes in cancer and other genetic disorders.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in